Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C
View abstract on PubMed
Summary
This summary is machine-generated.Peginterferon alfa-2b maintenance therapy did not prevent hepatocellular carcinoma (HCC) or significantly delay clinical events in chronic hepatitis C patients. However, it showed potential benefit for those with portal hypertension.
Area Of Science
- Hepatology
- Viral Hepatitis
- Oncology
Background
- Previous studies suggested low-dose interferon may delay hepatocellular carcinoma (HCC) and chronic hepatitis C progression.
- The EPIC3 program evaluated clinical events in patients with chronic hepatitis C and compensated cirrhosis.
Purpose Of The Study
- To investigate the incidence of clinical events in patients with chronic hepatitis C and compensated cirrhosis receiving peginterferon alfa-2b maintenance therapy.
- To assess the efficacy of peginterferon alfa-2b in preventing HCC and delaying disease progression.
Main Methods
- An open-label randomized study included patients with chronic hepatitis C who failed prior interferon alfa plus ribavirin treatment.
- Patients received either peginterferon alfa-2b (0.5 μg/kg/week) or no treatment for up to 5 years.
- The primary endpoint was the time to the first clinical event (hepatic decompensation, HCC, death, or liver transplantation).
Main Results
- No significant difference in time to first clinical event was observed between the peginterferon alfa-2b group and controls.
- Peginterferon alfa-2b did not decrease the incidence of HCC development.
- Time to disease progression was significantly longer in the peginterferon alfa-2b group.
- A subgroup analysis revealed that peginterferon alfa-2b significantly increased time to first clinical event in patients with baseline portal hypertension.
Conclusions
- Maintenance therapy with peginterferon alfa-2b is not universally indicated for chronic hepatitis C patients and does not prevent HCC.
- Long-term suppressive therapy with peginterferon alfa-2b may offer clinical benefits for patients with pre-existing portal hypertension.